INDIANAPOLIS, Oct. 31, 2020 /PRNewswire/ -- Eli Lilly and
Company (NYSE: LLY) and Incyte (NASDAQ: INCY) announced today
new data for baricitinib will be presented at the 29th
annual European Academy of Dermatology and Venereology (EADV)
Congress taking place virtually October
29-31, 2020. The data reinforce Lilly's commitment to
developing medicines for the treatment of dermatologic diseases
such as moderate to severe atopic dermatitis (AD). AD—also
known as eczema—is a chronic inflammatory skin disorder that causes
intense skin itching, redness, rash and sores.
At this year's virtual EADV meeting, data from BREEZE-AD3, a
Phase 3 study evaluating the long-term efficacy and safety of
baricitinib in adult patients with moderate to severe AD will be
shared. In the study, responders as assessed by the validated
Investigator Global Assessment score of "clear or almost clear"
skin (vIGA 0,1) and partial responders (vIGA 2) from one of the
16-week originating studies entered and continued treatment with
baricitinib 2-mg or 4-mg once daily for an additional 52 weeks. At
the start of BREEZE-AD3 (after 16 weeks of treatment in the
originating studies), 45.7% of responders and partial responders on
4-mg of baricitinib had a vIGA-AD score of 0 or 1, while 40% had a
vIGA-AD score of 0 or 1 after 68 weeks of continuous therapy.
Similarly, at the start of BREEZE-AD3 46.3% of responders and
partial responders on 2-mg of baricitinib had a vIGA-AD score of 0
or 1, while 50% had a vIGA-AD score of 0 or 1 after 68 weeks of
continuous therapy. These results indicate that baricitinib 4-mg
and 2-mg dose groups were able to maintain clear or almost clear
skin response rates through the 68-week treatment period. The
safety profile in this study was consistent with the known safety
findings of baricitinib in previous 16-week, placebo-controlled AD
studies.
"Baricitinib is part of a class of oral medicines called JAK
inhibitors. These data support its potential use as a treatment for
adults with moderate to severe AD," said Jonathan Silverberg, director of clinical
research at The George Washington University
School of Medicine and Health Sciences. "These results
demonstrate that baricitinib's efficacy at achieving clear or
almost clear skin could be sustained with continuous
treatment."
"At Lilly, we recognize the sacrifices that people living with
dermatologic diseases like AD are making to address the symptoms of
this chronic, relapsing skin disease," said Lotus Mallbris, M.D.,
Ph.D., vice president of immunology development at
Lilly. "We're encouraged by the long-term baricitinib efficacy
and safety data being presented at EADV, which reinforce the
potential role this medicine could play in helping people living
with AD."
Earlier this week, Lilly announced baricitinib received approval
in the European Union for the treatment of adult patients with
moderate to severe AD who are candidates for systemic therapy. The
approved EU Product Information for baricitinib can be found
here. Lilly has submitted these data to major regulatory
authorities around the world and continues to interact with several
regulators to seek approval for baricitinib as a medicine for
AD.
For more information about the Lilly data being presented at
this year's virtual EADV meeting, please visit
https://eadvvirtualcongress.org/.
Baricitinib, an oral JAK1/JAK2 inhibitor discovered by Incyte,
is developed by Lilly under license from Incyte.
Indication and Usage for OLUMIANT (baricitinib) tablets
(in the United States) for RA
patients
OLUMIANT® (baricitinib) 2-mg is indicated for
the treatment of adult patients with moderately to severely active
rheumatoid arthritis who have had an inadequate response to one or
more tumor necrosis factor (TNF) antagonist
therapies. Limitation of Use: Not recommended for use in
combination with other JAK inhibitors, biologic disease-modifying
antirheumatic drugs (DMARDs), or with potent immunosuppressants
such as azathioprine and cyclosporine.
IMPORTANT SAFETY INFORMATION FOR OLUMIANT (baricitinib)
TABLETS
WARNING: SERIOUS INFECTIONS, MALIGNANCY, AND
THROMBOSIS
SERIOUS INFECTIONS: Patients treated with
Olumiant are at risk for developing serious infections that may
lead to hospitalization or death. Most patients who developed these
infections were taking concomitant immunosuppressants such as
methotrexate or corticosteroids. If a serious infection develops,
interrupt Olumiant until the infection is controlled. Reported
infections include:
- Active tuberculosis (TB), which may present with pulmonary
or extrapulmonary disease. Test patients for latent TB before
initiating Olumiant and during therapy. If positive, start
treatment for latent infection prior to Olumiant use.
- Invasive fungal infections, including candidiasis and
pneumocystosis. Patients with invasive fungal infections may
present with disseminated, rather than localized, disease.
- Bacterial, viral, and other infections due to opportunistic
pathogens.
Carefully consider the risks and benefits of Olumiant prior
to initiating therapy in patients with chronic or recurrent
infection.
Closely monitor patients for the development of signs and
symptoms of infection during and after treatment with Olumiant
including the possible development of TB in patients who tested
negative for latent TB infection prior to initiating
therapy.
MALIGNANCIES: Lymphoma and other
malignancies have been observed in patients treated with
Olumiant.
THROMBOSIS: Thrombosis, including deep
venous thrombosis (DVT) and pulmonary embolism (PE), has been
observed at an increased incidence in patients treated with
Olumiant compared to placebo. In addition, there were cases of
arterial thrombosis. Many of these adverse events were serious and
some resulted in death. Patients with symptoms of thrombosis should
be promptly evaluated.
WARNINGS AND PRECAUTIONS
SERIOUS INFECTIONS: The most common serious
infections reported with Olumiant included pneumonia, herpes
zoster and urinary tract infection. Among opportunistic infections,
tuberculosis, multidermatomal herpes zoster, esophageal
candidiasis, pneumocystosis, acute histoplasmosis, cryptococcosis,
cytomegalovirus and BK virus were reported with Olumiant. Some
patients have presented with disseminated rather than local disease
and were often taking concomitant immunosuppressants such as
methotrexate or corticosteroids. Avoid Olumiant in patients with an
active, serious infection, including localized infections. Consider
the risks and benefits of treatment prior to initiating Olumiant in
patients:
- with chronic or recurrent infection
- who have been exposed to TB
- with a history of a serious or an opportunistic infection
- who have resided or traveled in areas of endemic tuberculosis
or endemic mycoses; or
- with underlying conditions that may predispose them to
infection.
Closely monitor patients for infections during and after
Olumiant treatment. Interrupt Olumiant if a patient develops a
serious infection, an opportunistic infection, or sepsis. Do not
resume Olumiant until the infection is controlled.
Tuberculosis – Before initiating
Olumiant evaluate and test patients for latent or active
infection and treat patients with latent TB with standard
antimycobacterial therapy. Olumiant should not be given to patients
with active TB. Consider anti-TB therapy prior to initiating
Olumiant in patients with a history of latent or active TB in whom
an adequate course of treatment cannot be confirmed, and for
patients with a negative test for latent TB but who have risk
factors for TB infection. Monitor patients for TB during Olumiant
treatment.
Viral Reactivation – Viral reactivation,
including cases of herpes virus reactivation (e.g., herpes zoster),
were reported in clinical studies with Olumiant. If a patient
develops herpes zoster, interrupt Olumiant treatment until the
episode resolves.
The impact of Olumiant on chronic viral hepatitis reactivation
is unknown. Screen for viral hepatitis in accordance with clinical
guidelines before initiating Olumiant.
MALIGNANCY AND LYMPHOPROLIFERATIVE
DISORDERS: Malignancies were observed in Olumiant
clinical studies. Consider the risks and benefits of Olumiant prior
to initiating therapy in patients with a known malignancy other
than a successfully treated non-melanoma skin cancer (NMSC) or when
considering continuing Olumiant in patients who develop a
malignancy. NMSCs were reported in patients treated with Olumiant.
Periodic skin examination is recommended for patients who are at
increased risk for skin cancer.
THROMBOSIS: Thrombosis, including DVT and
PE, has been observed at an increased incidence in Olumiant-treated
patients compared to placebo. In addition, arterial thrombosis
events in the extremities have been reported in clinical studies
with Olumiant. Many of these adverse events were serious and some
resulted in death. There was no clear relationship between platelet
count elevations and thrombotic events. Use Olumiant with
caution in patients who may be at increased risk of thrombosis. If
clinical features of DVT/PE or arterial thrombosis occur, evaluate
patients promptly and treat appropriately.
GASTROINTESTINAL PERFORATIONS: Gastrointestinal
perforations have been reported in Olumiant clinical studies,
although the role of JAK inhibition in these events is not known.
Use Olumiant with caution in patients who may be at increased
risk for gastrointestinal perforation (e.g., patients with a
history of diverticulitis). Promptly evaluate patients who present
with new onset abdominal symptoms for early identification of
gastrointestinal perforation.
LABORATORY ABNORMALITIES:
Neutropenia – Olumiant treatment was
associated with an increased incidence of neutropenia (absolute
neutrophil count [ANC] <1000 cells/mm3) compared
to placebo. Avoid initiation or interrupt Olumiant treatment in
patients with an ANC <1000 cells/mm3. Evaluate
at baseline and thereafter according to routine patient
management.
Lymphopenia – Absolute lymphocyte
count (ALC) <500 cells/mm3 were reported in
Olumiant clinical trials. Lymphocyte counts less than the lower
limit of normal were associated with infection in patients treated
with Olumiant, but not placebo. Avoid initiation or interrupt
Olumiant treatment in patients with an ALC
<500 cells/mm3. Evaluate at baseline and
thereafter according to routine patient management.
Anemia – Decreases in hemoglobin
levels to <8 g/dL were reported in Olumiant clinical
trials. Avoid initiation or interrupt Olumiant treatment in
patients with hemoglobin <8 g/dL. Evaluate at baseline and
thereafter according to routine patient management.
Liver Enzyme Elevations – Olumiant
treatment was associated with increased incidence of liver enzyme
elevation compared to placebo. Increases of ALT ≥5x upper limit of
normal (ULN) and increases of AST ≥10x ULN were observed in
patients in Olumiant clinical trials.
Evaluate at baseline and thereafter according to routine patient
management. Promptly investigate the cause of liver enzyme
elevation to identify potential cases of drug-induced liver injury.
If increases in ALT or AST are observed and drug-induced liver
injury is suspected, interrupt Olumiant until this diagnosis is
excluded.
Lipid Elevations – Treatment with
Olumiant was associated with increases in lipid parameters,
including total cholesterol, low-density lipoprotein cholesterol
and high-density lipoprotein cholesterol. Assess lipid parameters
approximately 12 weeks following Olumiant initiation. Manage
patients according to clinical guidelines for the management of
hyperlipidemia.
VACCINATIONS: Avoid use of live vaccines with
Olumiant. Update immunizations in agreement with current
immunization guidelines prior to initiating Olumiant therapy.
HYPERSENSITIVITY: Reactions such as angioedema,
urticaria, and rash that may reflect drug sensitivity have been
observed in patients receiving Olumiant, including serious
reactions. If a serious hypersensitivity reaction occurs, promptly
discontinue Olumiant while evaluating the potential causes of the
reaction.
ADVERSE REACTIONS
Most common adverse reactions
include: upper respiratory tract infections (16.3%, 11.7%), nausea
(2.7%, 1.6%), herpes simplex (0.8%, 0.7%) and herpes zoster (1.0%,
0.4%) for Olumiant 2 mg and placebo, respectively.
USE IN SPECIFIC POPULATIONS
PREGNANCY AND LACTATION: No information is available
to support the use of Olumiant in pregnancy or lactation. Advise
women not to breastfeed during treatment with Olumiant.
HEPATIC AND RENAL IMPAIRMENT: Olumiant is not
recommended in patients with severe hepatic impairment or in
patients with severe renal impairment.
Please click to access full Prescribing
Information, including Boxed Warning about Serious infections,
Malignancies, and Thrombosis, and Medication Guide.
BA HCP ISI 09JUL2020
About OLUMIANT®
OLUMIANT
is a once-daily, oral JAK inhibitor approved in the U.S. for the
treatment of adults with moderately- to severely active rheumatoid
arthritis who have had an inadequate response to one or more TNF
inhibitor therapies, and approved outside of the U.S. for patients
with moderately- to severely active rheumatoid arthritis who have
had an inadequate response to one or more
DMARDs.1 There are four known JAK enzymes: JAK1,
JAK2, JAK3 and TYK2. JAK-dependent cytokines have been implicated
in the pathogenesis of a number of inflammatory and autoimmune
diseases.2 OLUMIANT has greater inhibitory potency
at JAK1, JAK2 and TYK2 relative to JAK3; however, the relevance of
inhibition of specific JAK enzymes to therapeutic effectiveness is
not currently known.1 OLUMIANT is approved in more
than 70 countries.
In December 2009, Lilly and Incyte
announced an exclusive worldwide license and collaboration
agreement for the development and commercialization of baricitinib
and certain follow-on compounds for patients with inflammatory and
autoimmune diseases.
About Atopic Dermatitis
Atopic dermatitis (AD), or
atopic eczema, is a chronic, relapsing skin disease characterized
by intense itching, dry skin and inflammation that can be present
on any part of the body.3 AD is a
heterogeneous disease both biologically and clinically, but may be
characterized by chronic symptoms of itch, redness and skin damage
that are often punctuated with episodic, sometimes unpredictable,
flares or
exacerbations.4,5 AD
affects approximately one-three percent of adults
worldwide.6
Moderate to severe AD is characterized by intense itching,
resulting in visibly damaged skin.7 Like
other chronic inflammatory diseases, AD is immune-mediated and
involves a complex interplay of immune cells and inflammatory
cytokines.8
About Lilly in Dermatology
By following the science
through unchartered territory, we continue Lilly's legacy of
delivering innovative medicines that address unmet needs and have
significant impacts on people's lives around the world.
Skin-related diseases are more than skin deep. We understand the
devastating impact this can have on people's lives. At Lilly, we
are relentlessly pursuing a robust dermatology pipeline to provide
innovative, patient-centered solutions so patients with
skin-related diseases can aspire to live life without
limitations.
About Eli Lilly and Company
Lilly is a global
health care leader that unites caring with discovery to create
medicines that make life better for people around the world. We
were founded more than a century ago by a man committed to creating
high-quality medicines that meet real needs, and today we remain
true to that mission in all our work. Across the globe, Lilly
employees work to discover and bring life-changing medicines to
those who need them, improve the understanding and management of
disease, and give back to communities through philanthropy and
volunteerism. To learn more about Lilly, please visit us
at lilly.com and lilly.com/newsroom. P-LLY
About Incyte
Incyte is a Wilmington, Delaware-based, global
biopharmaceutical company focused on finding solutions for serious
unmet medical needs through the discovery, development and
commercialization of proprietary therapeutics. For additional
information on Incyte, please visit Incyte.com and follow
@Incyte.
This press release contains forward-looking statements (as that
term is defined in the Private Securities Litigation Reform Act of
1995) about OLUMIANT (baricitinib) as a treatment for patients with
moderate to severe atopic dermatitis and reflects Lilly's
and Incyte's current beliefs. However, as with any
pharmaceutical product, there are substantial risks and
uncertainties in the process of development and commercialization.
Among other things, there can be no guarantee the future study
results will be consistent with the results to date, that OLUMIANT
will receive additional regulatory approvals, or that it will be
commercially successful. For further discussion of these and other
risks and uncertainties, see Lilly's and Incyte's most
recent respective Form 10-K and Form 10-Q filings with
the United States Securities and Exchange Commission. Except
as required by law, Lilly and Incyte undertake no duty to
update forward-looking statements to reflect events after the date
of this release.
Refer to:
|
Kristen Porter Basu,
basu_kristen_porter@lilly.com; 317-447-2199 (media)
|
|
Kevin Hern;
hern_kevin_r@lilly.com; 317-277-1838 (investors)
|
|
Catalina Loveman;
cloveman@incyte.com; +1-302-498-6171 (Incyte media)
|
|
Michael Booth, DPhil;
mbooth@incyte.com; +1-302-498-5914 (Incyte investors)
|
______________________________
1 Olumiant Prescribing Information, 2020.
2 Walker JG and Smith MD. J Rheumatol.
2005;32;1650-1653.
3 Zuberbier T, Orlow SJ, Paller AS, et al. Patient
perspectives on the management of atopic dermatitis. The Journal of
Allergy and Clinical Immunology. 2006;118: 226-32.
4 Thijs JL, Strickland I, Bruijnzeel-Koomen C, et.
al. Moving toward endotypes in atopic dermatitis: identification of
patient clusters based on serum biomarker analysis. The Journal of
Allergy and Clinical Immunology. 2017.
5 Langan SM, Thomas KS,
Williams HC. What is meant by "flare" in atopic dermatitis? A
systematic review and proposal. Arch Dermatol.
2006;142:1190-1196.
6 Nutten S. Atopic dermatitis: global epidemiology and
risk factors. Annals of Nutrition and Metabolism. 2015;66(suppl 1):
8-16.
7 Yosipovitch G, Papoiu AD. What causes itch in atopic
dermatitis? Current Allergy and Asthma Reports. 2008;8:306-311.
8 Weidinger, S, Novak, N. Atopic dermatitis. The Lancet
Volume 387. 2016;10023:1109-1122.
View original content to download
multimedia:http://www.prnewswire.com/news-releases/eadv-2020-lilly-and-incyte-showcase-new-data-for-baricitinib-for-the-treatment-of-moderate-to-severe-atopic-dermatitis-301163842.html
SOURCE Eli Lilly and Company